The molecular tumor board solutions market size has grown rapidly in recent years. It will grow from $1.53 billion in 2025 to $1.74 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to expansion of precision oncology programs, increasing availability of genomic sequencing data, growth of multidisciplinary cancer care teams, rising adoption of clinical decision support software, improved data sharing across oncology centers.
The molecular tumor board solutions market size is expected to see rapid growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing investments in personalized cancer treatment, rising demand for molecularly guided therapies, expansion of cloud deployment in healthcare, growing integration with clinical trial matching platforms, increasing adoption of ai-driven oncology analytics. Major trends in the forecast period include increasing use of AI-assisted variant interpretation, growing integration of multimodal genomic data, expansion of cloud-based tumor board platforms, rising adoption of collaborative decision support tools, enhanced focus on personalized oncology workflows.
The rising prevalence of cancer is expected to propel the growth of the molecular tumor board solutions market going forward. Cancer involves uncontrolled abnormal cell growth. Its prevalence is increasing due to lifestyle factors. Molecular tumor board solutions enhance cancer care by integrating genomic data and multidisciplinary expertise to guide personalized treatment. For instance, the World Health Organization projects over 35 million new cancer cases by 2050. Therefore, rising cancer prevalence is driving the growth of molecular tumor board solutions.
Leading companies operating in the molecular tumor board solutions market are focusing on developing innovative solutions, such as molecular profiling tests, to improve the accuracy and effectiveness of cancer diagnostics and treatment planning. Molecular profiling tests are diagnostic tools that analyze a tumor’s genetic and molecular characteristics to guide personalized cancer treatment decisions. For instance, in April 2025, Guardant Health Inc., a US-based biotechnology and precision oncology company, launched Guardant360 Tissue, an advanced molecular profiling test for tumor tissue that integrates comprehensive multiomic analysis, including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data. This test, powered by the Guardant Infinity smart liquid biopsy platform, delivers a more complete and multidimensional view of cancer, enabling higher-resolution tumor classification and subtyping. Guardant360 Tissue provides results in under two weeks, is covered by Medicare for eligible patients, and aims to strengthen precision oncology by offering deeper insights to guide treatment decisions, including therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapies.
In September 2024, Labcorp Holdings Inc., a US-based healthcare company, acquired BioReference Health LLC for $237.5 million. Through this acquisition, Labcorp aims to expand its laboratory services network and improve access to clinical testing for patients, physicians, and customers in key regions. BioReference Health LLC is a US-based company that offers molecular tumor board solutions through comprehensive genomic testing services.
Major companies operating in the molecular tumor board solutions market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Illumina Inc., Novogene Co. Ltd., QIAGEN N.V., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Mayo Clinic Laboratories, Sectra AB, GenomOncology LLC, MedGenome Labs Ltd., Burning Rock Biotech Limited, NantHealth Inc., SOPHiA GENETICS SA, Variantyx Inc., Baylor Genetics, Molecular Health GmbH, PierianDx Inc., Oncompass Medicine, CureMatch Inc.
North America was the largest region in the molecular tumor board solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular tumor board solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the molecular tumor board solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the molecular tumor board solutions market by increasing costs of imported computing hardware, genomic analysis software licenses, cloud infrastructure services, and data security technologies. Hospitals and cancer centers in North America and Europe are most affected due to dependence on advanced imported IT and bioinformatics solutions, while Asia-Pacific faces higher costs for platform localization and deployment. These tariffs are increasing total cost of ownership and slowing adoption in smaller institutions. At the same time, they are encouraging local software development, regional cloud partnerships, and domestically hosted precision oncology platforms.
The molecular tumor board solutions market research report is one of a series of new reports that provides molecular tumor board solutions market statistics, including molecular tumor board solutions industry global market size, regional shares, competitors with a molecular tumor board solutions market share, detailed molecular tumor board solutions market segments, market trends and opportunities, and any further data you may need to thrive in the molecular tumor board solutions industry. This molecular tumor board solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Molecular tumor board solutions are sophisticated platforms developed to support multidisciplinary clinical teams in conducting comprehensive cancer case evaluations by integrating patient-specific molecular and genomic data. These solutions assist in identifying actionable genetic mutations, assessing targeted treatment options, and reviewing appropriate clinical trials, thereby enabling informed and personalized therapeutic decisions.
The primary types of components in molecular tumor board solutions are software and services. Software consists of digital platforms and applications designed to integrate patient data, analyze genetic profiles, and generate treatment recommendations for cancer care. These solutions can be deployed through on-premises or cloud-based models and support applications such as clinical decision support, genomic data interpretation, patient management, and others, serving end-users such as hospitals, cancer centers, research institutes, and others.
The molecular tumor board solutions market includes revenues earned by entities through providing expert clinical consultations, personalized treatment recommendations, and decision-support services to healthcare providers and patients. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The molecular tumor board solutions market size is expected to see rapid growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing investments in personalized cancer treatment, rising demand for molecularly guided therapies, expansion of cloud deployment in healthcare, growing integration with clinical trial matching platforms, increasing adoption of ai-driven oncology analytics. Major trends in the forecast period include increasing use of AI-assisted variant interpretation, growing integration of multimodal genomic data, expansion of cloud-based tumor board platforms, rising adoption of collaborative decision support tools, enhanced focus on personalized oncology workflows.
The rising prevalence of cancer is expected to propel the growth of the molecular tumor board solutions market going forward. Cancer involves uncontrolled abnormal cell growth. Its prevalence is increasing due to lifestyle factors. Molecular tumor board solutions enhance cancer care by integrating genomic data and multidisciplinary expertise to guide personalized treatment. For instance, the World Health Organization projects over 35 million new cancer cases by 2050. Therefore, rising cancer prevalence is driving the growth of molecular tumor board solutions.
Leading companies operating in the molecular tumor board solutions market are focusing on developing innovative solutions, such as molecular profiling tests, to improve the accuracy and effectiveness of cancer diagnostics and treatment planning. Molecular profiling tests are diagnostic tools that analyze a tumor’s genetic and molecular characteristics to guide personalized cancer treatment decisions. For instance, in April 2025, Guardant Health Inc., a US-based biotechnology and precision oncology company, launched Guardant360 Tissue, an advanced molecular profiling test for tumor tissue that integrates comprehensive multiomic analysis, including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data. This test, powered by the Guardant Infinity smart liquid biopsy platform, delivers a more complete and multidimensional view of cancer, enabling higher-resolution tumor classification and subtyping. Guardant360 Tissue provides results in under two weeks, is covered by Medicare for eligible patients, and aims to strengthen precision oncology by offering deeper insights to guide treatment decisions, including therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapies.
In September 2024, Labcorp Holdings Inc., a US-based healthcare company, acquired BioReference Health LLC for $237.5 million. Through this acquisition, Labcorp aims to expand its laboratory services network and improve access to clinical testing for patients, physicians, and customers in key regions. BioReference Health LLC is a US-based company that offers molecular tumor board solutions through comprehensive genomic testing services.
Major companies operating in the molecular tumor board solutions market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Illumina Inc., Novogene Co. Ltd., QIAGEN N.V., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Mayo Clinic Laboratories, Sectra AB, GenomOncology LLC, MedGenome Labs Ltd., Burning Rock Biotech Limited, NantHealth Inc., SOPHiA GENETICS SA, Variantyx Inc., Baylor Genetics, Molecular Health GmbH, PierianDx Inc., Oncompass Medicine, CureMatch Inc.
North America was the largest region in the molecular tumor board solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular tumor board solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the molecular tumor board solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the molecular tumor board solutions market by increasing costs of imported computing hardware, genomic analysis software licenses, cloud infrastructure services, and data security technologies. Hospitals and cancer centers in North America and Europe are most affected due to dependence on advanced imported IT and bioinformatics solutions, while Asia-Pacific faces higher costs for platform localization and deployment. These tariffs are increasing total cost of ownership and slowing adoption in smaller institutions. At the same time, they are encouraging local software development, regional cloud partnerships, and domestically hosted precision oncology platforms.
The molecular tumor board solutions market research report is one of a series of new reports that provides molecular tumor board solutions market statistics, including molecular tumor board solutions industry global market size, regional shares, competitors with a molecular tumor board solutions market share, detailed molecular tumor board solutions market segments, market trends and opportunities, and any further data you may need to thrive in the molecular tumor board solutions industry. This molecular tumor board solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Molecular tumor board solutions are sophisticated platforms developed to support multidisciplinary clinical teams in conducting comprehensive cancer case evaluations by integrating patient-specific molecular and genomic data. These solutions assist in identifying actionable genetic mutations, assessing targeted treatment options, and reviewing appropriate clinical trials, thereby enabling informed and personalized therapeutic decisions.
The primary types of components in molecular tumor board solutions are software and services. Software consists of digital platforms and applications designed to integrate patient data, analyze genetic profiles, and generate treatment recommendations for cancer care. These solutions can be deployed through on-premises or cloud-based models and support applications such as clinical decision support, genomic data interpretation, patient management, and others, serving end-users such as hospitals, cancer centers, research institutes, and others.
The molecular tumor board solutions market includes revenues earned by entities through providing expert clinical consultations, personalized treatment recommendations, and decision-support services to healthcare providers and patients. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Molecular Tumor Board Solutions Market Characteristics
3. Molecular Tumor Board Solutions Market Supply Chain Analysis
4. Global Molecular Tumor Board Solutions Market Trends and Strategies
5. Molecular Tumor Board Solutions Market Analysis of End Use Industries
7. Global Molecular Tumor Board Solutions Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Molecular Tumor Board Solutions Total Addressable Market (TAM) Analysis for the Market
9. Molecular Tumor Board Solutions Market Segmentation
10. Molecular Tumor Board Solutions Market Regional and Country Analysis
11. Asia-Pacific Molecular Tumor Board Solutions Market
12. China Molecular Tumor Board Solutions Market
13. India Molecular Tumor Board Solutions Market
14. Japan Molecular Tumor Board Solutions Market
15. Australia Molecular Tumor Board Solutions Market
16. Indonesia Molecular Tumor Board Solutions Market
17. South Korea Molecular Tumor Board Solutions Market
18. Taiwan Molecular Tumor Board Solutions Market
19. South East Asia Molecular Tumor Board Solutions Market
20. Western Europe Molecular Tumor Board Solutions Market
21. UK Molecular Tumor Board Solutions Market
22. Germany Molecular Tumor Board Solutions Market
23. France Molecular Tumor Board Solutions Market
24. Italy Molecular Tumor Board Solutions Market
25. Spain Molecular Tumor Board Solutions Market
26. Eastern Europe Molecular Tumor Board Solutions Market
27. Russia Molecular Tumor Board Solutions Market
28. North America Molecular Tumor Board Solutions Market
29. USA Molecular Tumor Board Solutions Market
30. Canada Molecular Tumor Board Solutions Market
31. South America Molecular Tumor Board Solutions Market
32. Brazil Molecular Tumor Board Solutions Market
33. Middle East Molecular Tumor Board Solutions Market
34. Africa Molecular Tumor Board Solutions Market
36. Molecular Tumor Board Solutions Market Competitive Landscape and Company Profiles
37. Molecular Tumor Board Solutions Market Other Major and Innovative Companies
40. Molecular Tumor Board Solutions Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Molecular Tumor Board Solutions Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses molecular tumor board solutions market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for molecular tumor board solutions? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The molecular tumor board solutions market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Component: Software; Services2) By Deployment Mode: On-Premises; Cloud-Based
3) By Application: Clinical Decision Support; Genomic Data Interpretation; Patient Management; Other Applications
4) By End-User: Hospitals; Cancer Centers; Research Institutes; Other End-Users
Subsegments:
1) By Software: Clinical Decision Support; Data Analytics; Reporting And Visualization; Integration Platforms2) By Services: Consulting; Implementation; Training And Support; Maintenance And Upgrades
Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Siemens Healthineers AG; Koninklijke Philips N.V.; Illumina Inc.; Novogene Co. Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Caris Life Sciences Inc.; Mayo Clinic Laboratories; Sectra AB; GenomOncology LLC; MedGenome Labs Ltd.; Burning Rock Biotech Limited; NantHealth Inc.; SOPHiA GENETICS SA; Variantyx Inc.; Baylor Genetics; Molecular Health GmbH; PierianDx Inc.; Oncompass Medicine; CureMatch Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Molecular Tumor Board Solutions market report include:- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Illumina Inc.
- Novogene Co. Ltd.
- QIAGEN N.V.
- Myriad Genetics Inc.
- BGI Genomics Co. Ltd.
- Guardant Health Inc.
- Caris Life Sciences Inc.
- Mayo Clinic Laboratories
- Sectra AB
- GenomOncology LLC
- MedGenome Labs Ltd.
- Burning Rock Biotech Limited
- NantHealth Inc.
- SOPHiA GENETICS SA
- Variantyx Inc.
- Baylor Genetics
- Molecular Health GmbH
- PierianDx Inc.
- Oncompass Medicine
- CureMatch Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.74 Billion |
| Forecasted Market Value ( USD | $ 2.87 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
